News
Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...
Texas Attorney General Ken Paxton has sued Eli Lilly, alleging the drugmaker offered illegal incentives to providers, leading ...
Doctors advise most patients on GLP-1 obesity drugs such as Wegovy and Zepbound to stay on them to keep the weight off, but ...
Eli Lilly is a leader in the market for GLP-1 medicines. The company's Zepbound, indicated for weight loss, is racking up ...
Paxton's office said the company supplied free nurses to help care for patients who received its drugs, as well as ...
Eli Lilly's Mounjaro and Zepbound drove Q2 2025 revenue up 38% and EPS up 92% YoY. Read why LLY stock's recent 20% pullback ...
Some patients reluctantly shifted to save money while others have appealed for coverage of Zepbound after having experienced better weight-loss results and fewer side effects.
Doctors report insurance cuts are forcing many U.S. patients on Wegovy and Zepbound to pay high out-of-pocket costs.
A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring to U.S. biopharma.
As part of a new campaign, Whitley is partnering with Zepbound to break down the stigma surrounding obesity and inspire others to seek support and treatment.
Fact checked by Nick Blackmer With anti-obesity medications like Ozempic, Wegovy, and Zepbound exploding in popularity in ...
8h
WISH-TV on MSNAugust Indiana Economic Update
Lilly’s shares were impacted after a difficult month for its weight loss drug, A recent study showed the pill form of Lilly's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results